drughunter.com
8 minute read
Jun. 18, 2024

A Potential Best-in-Class PRC2 Inhibitor With the Ability to Reprogram Refractory, AR-Independent Prostate Tumors

ORIC-944

oral allosteric PRC2 inhibitor Ph. Ib for metastatic prostate cancer from imidazopyrimidine PRC2 inhibitors in patent literature AACR San Diego 2024, “New Drugs on the Horizon” Session ORIC Pharmaceuticals, South San Francisco, CA

Author:  
Reviewer:  
Editor:  
Loading...

twitterlinkedinemail

Other molecules you may be interested in